Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.
Josephine HarringtonAnne S HellkampKenneth W MahaffeyGuenter BreithardtJonathan L HalperinGraeme J HankeyRichard C BeckerChristopher C NesselScott D BerkowitzKeith A A FoxDaniel E SingerShaun G GoodmanManesh R PatelJonathan P PicciniPublished in: Journal of the American Heart Association (2024)
DAOH did not identify a treatment difference between patients randomized to rivaroxaban versus warfarin. This may be driven in part by the low overall event rates in atrial fibrillation anticoagulation trials, which leads to substantial left skew in measures of DAOH.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- direct oral anticoagulants
- left atrial appendage
- end stage renal disease
- heart failure
- newly diagnosed
- percutaneous coronary intervention
- ejection fraction
- healthcare
- chronic kidney disease
- peritoneal dialysis
- venous thromboembolism
- emergency department
- clinical trial
- acute coronary syndrome
- coronary artery disease
- patient reported outcomes
- mitral valve
- blood brain barrier
- phase ii
- combination therapy
- smoking cessation
- electronic health record